The announcement was made by Majmudar himself on Twitter, according to the report, though he did not state what his specific role within the company will be.
Prior to joining Amazon, Majmudar served as the associate director of Massachusetts General Hospital’s healthcare transformation lab and lectured at the Massachusetts Institute of Technology, according to the report.
Majmudar has advised tech companies in the past, according to CNBC, including diagnosis company Quanttus which aimed to track blood pressure from the wrist, but failed.
Amazon has not officially commented on the addition.
Rox Medical said last week it appointed former Philips exec Mike MacKinnon as its new chief executive officer.
Prior to joining San Clemente, Calif.-based Rox Medical, MacKinnon served as head of image guided technologies and devices sales for Royal Philips (NYSE:PHG). He joined Philips through its acquisition of Volcano, with which he served as Phoenix atherectomy and peripheral sales lead and GM, Rox Medical said.
MacKinnon also served as president and CEO of AtheroMed before Volcano acquired it in 2014.
“Despite the many classes of drugs available to physicians to treat hypertension, millions of patients still have blood pressures that are uncontrolled or resistant to treatment, leading to serious conditions including stroke, heart attack, heart failure and kidney disease. By diverting blood from the arteries to the veins via a small stent in a short, outpatient procedure, the impact of the Rox Coupler device on blood pressure has been shown to be long-lasting and immediate. I am excited to work with the physician-investigators on the FDA-approved US pivotal study to build the evidence for this potentially life-saving technology,” MacKinnon said in a press release.
“Mike is a seasoned medical device executive whose expertise lies in commercializing game-changing cardiovascular technologies. We are thrilled to bring Mike’s leadership and energy to the Rox team as this technology progresses to the market and potentially becomes the standard of care in hypertension,” board member David McIntyre said in a prepared statement.
SetPoint Medical said last week it named Murthy Simhambhatla as its new prez and CEO, replacing Anthony Arnold who has “decided to pursue other opportunities.”
Simhambhatla previously served as prez & CEO of medical aesthetics company Evolus, and has held positions as senior VP at Abbott (NYSE:ABT) and as president of Abbot Medical Optics, the Valencia, Calif.-based company said.
“The depth and breadth of Murthy’s expertise make him an ideal fit to lead SetPoint through the next phase of pivotal clinical study and commercialization. Murthy is uniquely qualified to advance SetPoint Medical to its full potential, building on the strong foundation of our proprietary bioelectronic medicine platform. The board and I would like to thank Tony for successfully leading the development of SetPoint’s proprietary device and advancing it through a U.S. first-in-human study. We wish Tony continued success in his next endeavor,” board chair Allan Will said in a prepared statement.
“SetPoint’s therapy offers a novel pathway to address unmet needs for patients with autoimmune diseases. I’m delighted to have the opportunity to lead SetPoint and to work with its innovative team to develop and commercialize our therapy for patients with autoimmune diseases,” Dr. Simhambhatla said in a press release.
Before joining the Belgrade, Mont.-based company, Lenzen served as senior VP and GM of Astora’s women’s health division, and has also held positions as VP of finance for American Medical Systems.
“Ms. Lenzen is an accomplished healthcare executive with significant financial expertise and we are pleased that she is joining our executive management team. In addition to the financial leadership she will provide to the organization, she is a strong strategic, cross-functional leader. Her appointment continues our commitment to building a highly skilled management team,” CEO Carl O’Connell said in a press release.
“I am excited to join the Xtant team and contribute to the Company’s growth strategy. Xtant has made considerable progress over the past year, and I look forward to helping the Company continue to transform its business and drive shareholder value,” Lenzen said in a prepared statement.
Brown has served in a number of roles in the medtech field, most recently as GM of a multi-site joint venture between Johnson & Johnson (NYSE:JNJ) and Steris (NYSE:STE). He has also served as GM of Boston Scientific and as worldwide operations manager at J&J, and as COO of Chatham Industries.
“I am very excited to have someone with Jeff’s credentials and industry knowledge joining our executive team. His proven track record of transformational leadership, operational excellence, and delivering results will be invaluable to Endologix. We remain focused on building a cohesive team and a strong culture of accountability, while continuing to innovate and position the Company for further operational improvements,” CEO John Onopchenko said in a prepared release.
“I am thrilled to be taking on this critical leadership role at Endologix, particularly during this transformational time. I look forward to working with the team to improve operations and to leverage our talent and innovative technology, with the ultimate goal of delivering superior products and services to our patients,” Brown said in a prepared statement.